Why the Cronos Group Stock Price Fell 18.3% in February

Cronos Group stock price tumbles on delay of earnings results due to accounting review, placing revenue growth into question.

| More on:
Question marks in a pile

Image source: Getty Images

The Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) stock price fell 18.3% in February. The market continues to fall and company-specific uncertainty remains high. This is making any prediction for the Cronos Group stock price very uncertain and precarious.

Fears of the potential severity of the coronavirus have ruled the market since February. This certainly continues today. As I write this article, I am struck by the downside that we are seeing. Cronos Group must deal not only with this, but also with sector and company-specific problems.  Let’s take a closer look.

Cronos Group stock price falls on results release delay

Cronos Group took the unusual move of delaying the release of its fourth-quarter and year-end 2019 results. Obviously, this took the stock down hard in February. We can only imagine what bad news awaits us from Cronos Group.

The earnings release was initially scheduled for February 27.  But a few days before this date, the company notified investors that there was a delay in the completion of financial statements. A few days later, the company filed a form 12b-25 with the U.S. Securities and Exchange Commission (SEC). This effectively provides the company with a 15-day extension of the filing due date. At this point, we are just waiting for this dreaded release.

Accounting review uncertainty to continue to take Cronos stock price down

The issue here is quite alarming. In the company’s SEC filing to delay the release, we got somewhat of an explanation. The accounting review is a review “of several bulk resin purchases and sales of products through the wholesale channel”. “The appropriateness of the recognition of revenue from those transactions” is being questioned. This effectively places past as well as future revenue growth into question.

The accounting issue also compounds the already existing problems in the cannabis sector. Problems such as a troubled legalization process in Canada and an oversupply of cannabis have taken a toll. A general bubble-like mentality in cannabis stock prices have already wreaked havoc on the sector.

On the positive side, Cronos Group remains well supported by its partnership with tobacco giant Altria Group Inc. This partnership has given Cronos Group greater financial capacity as well as leading technology and research and development capabilities. This partnership brings benefits to Cronos in distribution, capacity, brand development, and intellectual property.

Financially, Cronos Group reported revenue of $12.7 million in its latest released quarter (Q3 2019). This represents a 24% increase versus the prior quarter and a 238% increase versus the prior year. Cronos Group had $2 billion in cash as of the third quarter, and a cash burn of $100 million. Cronos stock price valuation remains problematic, at 77 times sales.

Going forward, this accounting review has placed a serious amount of uncertainty on the future of Cronos Group stock price. This, at a time when market uncertainty continues to escalate to near unprecedented levels.

Foolish bottom line

Cronos Group stock price suffered in February due to a combination of both macro factors, and sector and company-specific factors. The stock continues to be very richly valued. With revenue growth being put into question, the risk to the stock price remains high.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Are Cannabis Stocks a Good Buy in March 2023?

Cannabis stocks like Canopy Growth Corp (TSX:WEED) are still being talked about, but are they worth buying?

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Down 26% in a Month, Is Canopy a Buy Today?

Canopy Growth Corp (TSX:WEED) is down 26% in a month. Is it time to start bottom fishing?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

What’s Next for Aurora Cannabis Stock?

Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock: Undervalued Gem or Falling Knife?

Canopy Growth remains a high-risk bet, despite falling 95% from all-time highs. Let's see why you need to avoid WEED…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

3 Things to Know About Canopy Growth Stock After Earnings

A new focus on profitability and sustainability might stop the cash burn at Canopy Growth, so the stock can see…

Read more »

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »